Article Versions Notes

Herta T, Hahn M, Maier M, Fischer J, Niemeyer J, Hönemann M, Böhlig A, Gerhardt F, Schindler A, Schumacher J, et al. Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. Pathogens. 2022; 11(5):517. https://doi.org/10.3390/pathogens11050517

Herta, Toni, Magdalena Hahn, Melanie Maier, Janett Fischer, Johannes Niemeyer, Mario Hönemann, Albrecht Böhlig, Florian Gerhardt, Aaron Schindler, Jonas Schumacher, and et al. 2022. "Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection" Pathogens 11, no. 5: 517. https://doi.org/10.3390/pathogens11050517

Herta, T., Hahn, M., Maier, M., Fischer, J., Niemeyer, J., Hönemann, M., Böhlig, A., Gerhardt, F., Schindler, A., Schumacher, J., Berg, T., Wiegand, J., & van Bömmel, F. (2022). Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. Pathogens, 11(5), 517. https://doi.org/10.3390/pathogens11050517